• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Personal Stories
    • Our Partners
    • Newsletter
  • About Pompe
  • Blog
  • Links
  • Connections
Select Page
Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

by Brad Crittenden | Feb 25, 2019 | News

Amicus Therapeutics announced today that they have received Breakthrough Therapy Designation (BTD) for their AT-GAA treatment for Pompe disease.

Recent Posts

  • Amicus Therapeutics Provides Updates for AT-GAA for Pompe Disease
  • IPA Update – Q4 2019
  • Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
  • Audentes Therapeutics Update on Pompe and Other Programs
  • 2019 CAP Annual General Meeting
  • Terms
  • Privacy

Copyright © 2006 - 2020 Canadian Association of Pompe | Developed by PacificByte

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok